Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis
| Autor: | Jameel Nazir, Con Kelleher, Isaac Odeyemi, Samuel Aballéa, K. Maman, Colette Mankowski, Zalmai Hakimi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Tolterodine Tartrate Urology Network Meta-Analysis 030232 urology & nephrology Muscarinic Antagonists Benzilates 03 medical and health sciences 0302 clinical medicine Fesoterodine medicine Darifenacin Humans 030212 general & internal medicine Benzhydryl Compounds Oxybutynin Solifenacin Urinary Bladder Overactive business.industry Solifenacin Succinate medicine.disease Treatment Outcome Overactive bladder Tolerability Mandelic Acids Propiverine Neurology (clinical) Tolterodine business medicine.drug |
| Zdroj: | Neurourology and Urodynamics. 37:986-996 |
| ISSN: | 0733-2467 |
| DOI: | 10.1002/nau.23413 |
| Popis: | Aims To compare efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents for the treatment of overactive bladder (OAB). Methods Literature searches of MEDLINE, Embase, and the Cochrane Library were undertaken to identify randomized controlled trials in OAB (2000-2015) for antimuscarinic agents. A network meta-analysis (NMA) was performed to estimate efficacy and tolerability outcomes for solifenacin 5 mg/day relative to other antimuscarinics. Results The NMA included 53 eligible trials (published, n = 48; unpublished on search date, n = 5). Solifenacin 5 mg/day was significantly more effective than tolterodine 4 mg/day for reducing incontinence and urgency urinary incontinence (UUI) episodes, but significantly less effective than solifenacin 10 mg/day for micturition; no other statistically significant differences were noted for efficacy. Solifenacin 5 mg/day had a statistically significant lower risk of dry mouth compared with darifenacin 15 mg/day, fesoterodine 8 mg/day, oxybutynin extended-release 10 mg/day, oxybutynin immediate-release (IR) 9-15 mg/day, tolterodine IR 4 mg/day, propiverine 20 mg/day, and solifenacin 10 mg/day. There were no significant differences between solifenacin 5 mg/day and other antimuscarinics for risk of blurred vision, or for 11 of 17 active comparators for risk of constipation. Conclusions This NMA suggests that the efficacy of solifenacin 5 mg/day is at least similar to other common antimuscarinics across the spectrum of OAB symptoms analyzed, and is more effective than tolterodine 4 mg/day in reducing incontinence and UUI episodes. Solifenacin 5 mg/day has a lower risk of dry mouth compared with several agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text